Vaccine Therapy in Treating Patients With Stage IV Melanoma
Completed · Phase 1/Phase 2
Conditions studied: Melanoma (Skin)
In brief
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Infusing the vaccine directly into a lymph node may cause a stronger immune response and kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy in treating patients who have stage IV melanoma.
Key facts
- Study ID
- NCT00033228
- Run by
- Mannkind Corporation
- People needed
- 19
- Starts
- 2002-01-01
- Expected to finish
- 2003-04-01
- Last updated by the study team
- 2011-05-12
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Arizona Cancer Center at University of Arizona Health Sciences Center — Tucson, Arizona, United States
- USC/Norris Comprehensive Cancer Center and Hospital — Los Angeles, California, United States
- Cancer Research Center at Boston Medical Center — Boston, Massachusetts, United States
- Mayo Clinic Cancer Center — Rochester, Minnesota, United States
- Earle A. Chiles Research Institute at Providence Portland Medical Center — Portland, Oregon, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.